Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non–small cell lung cancer
作者： Ahmad A. Tarhini , Imran Rafique , Theofanis Floros , Phu Tran , William E. Gooding
DOI: 10.1002/CNCR.30717
关键词:
摘要: … Combined rilotumumab and erlotinib had an acceptable safety profile, and the DCR met the prespecified criteria for success. In the EGFR WT group, the DCR exceeded published …
utsystem.edu 参考文章(40)
Michail Charakidis, Michael Boyer, Targeting MET and EGFR in NSCLC—what can we learn from the recently reported phase III trial of onartuzumab in combination with erlotinib in advanced non-small cell lung cancer? Translational lung cancer research. ,vol. 3, pp. 395- 396 ,(2014) , 10.3978/J.ISSN.2218-6751.2014.09.03
Athanasios Karampeazis, Alexandra Voutsina, John Souglakos, Nikos Kentepozidis, Stelios Giassas, Charalambos Christofillakis, Athanasios Kotsakis, Pavlos Papakotoulas, Ageliki Rapti, Maria Agelidou, Sofia Agelaki, Lambros Vamvakas, George Samonis, Dimitris Mavroudis, Vassilis Georgoulias, Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: A Hellenic Oncology Research Group (HORG) randomized phase 3 study Cancer. ,vol. 119, pp. 2754- 2764 ,(2013) , 10.1002/CNCR.28132
Hisato Kawakami, Isamu Okamoto, Kimio Yonesaka, Kunio Okamoto, Kiyoko Shibata, Yume Shinkai, Haruka Sakamoto, Michiko Kitano, Takao Tamura, Kazuto Nishio, Kazuhiko Nakagawa, The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells Oncotarget. ,vol. 5, pp. 11847- 11856 ,(2014) , 10.18632/ONCOTARGET.2663
M Zhu, R Tang, S Doshi, K S Oliner, S Dubey, Y Jiang, R C Donehower, T Iveson, E Y Loh, Y Zhang, Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression British Journal of Cancer. ,vol. 112, pp. 429- 437 ,(2015) , 10.1038/BJC.2014.649
L. V. Sequist, B. A. Waltman, D. Dias-Santagata, S. Digumarthy, A. B. Turke, P. Fidias, K. Bergethon, A. T. Shaw, S. Gettinger, A. K. Cosper, S. Akhavanfard, R. S. Heist, J. Temel, J. G. Christensen, J. C. Wain, T. J. Lynch, K. Vernovsky, E. J. Mark, M. Lanuti, A. J. Iafrate, M. Mino-Kenudson, J. A. Engelman, Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors Science Translational Medicine. ,vol. 3, ,(2011) , 10.1126/SCITRANSLMED.3002003
Floria Lizárraga, Renaud Poincloux, Maryse Romao, Guillaume Montagnac, Gaëlle Le Dez, Isabelle Bonne, Guillem Rigaill, Graça Raposo, Philippe Chavrier, Diaphanous-related formins are required for invadopodia formation and invasion of breast tumor cells. Cancer Research. ,vol. 69, pp. 2792- 2800 ,(2009) , 10.1158/0008-5472.CAN-08-3709
Alexa B. Turke, Kreshnik Zejnullahu, Yi-Long Wu, Youngchul Song, Dora Dias-Santagata, Eugene Lifshits, Luca Toschi, Andrew Rogers, Tony Mok, Lecia Sequist, Neal I. Lindeman, Carly Murphy, Sara Akhavanfard, Beow Y. Yeap, Yun Xiao, Marzia Capelletti, A. John Iafrate, Charles Lee, James G. Christensen, Jeffrey A. Engelman, Pasi A. Jänne, Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC Cancer Cell. ,vol. 17, pp. 77- 88 ,(2010) , 10.1016/J.CCR.2009.11.022
Eric Van Cutsem, Cathy Eng, Elzbieta Nowara, Anna Świeboda-Sadlej, Niall C Tebbutt, Edith Mitchell, Irina Davidenko, Joe Stephenson, Elena Elez, Hans Prenen, Hongjie Deng, Rui Tang, Ian McCaffery, Kelly S Oliner, Lisa Chen, Jennifer Gansert, Elwyn Loh, Dominic Smethurst, Josep Tabernero, None, Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer. Clinical Cancer Research. ,vol. 20, pp. 4240- 4250 ,(2014) , 10.1158/1078-0432.CCR-13-2752
Laura P. Stabile, Mary E. Rothstein, Phouthone Keohavong, Diana Lenzner, Stephanie R. Land, Autumn L. Gaither-Davis, K. Jin Kim, Naftali Kaminski, Jill M. Siegfried, Targeting of Both the c-Met and EGFR Pathways Results in Additive Inhibition of Lung Tumorigenesis in Transgenic Mice Cancers. ,vol. 2, pp. 2153- 2170 ,(2010) , 10.3390/CANCERS2042153
J. A. Engelman, K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland, J. O. Park, N. Lindeman, C.-M. Gale, X. Zhao, J. Christensen, T. Kosaka, A. J. Holmes, A. M. Rogers, F. Cappuzzo, T. Mok, C. Lee, B. E. Johnson, L. C. Cantley, P. A. Janne, MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling Science. ,vol. 316, pp. 1039- 1043 ,(2007) , 10.1126/SCIENCE.1141478